Back to discover
Disease

Hypersensitivity, Immediate

Late-stage therapeutic developmentEmerging research
MeSHHypersensitivity, Immediate
2
Publications
6
Clinical trials
2020
Latest publication
Latest activity
beta

Recent clinical, regulatory, research and industry developments relating to this disease.

What's happening now

An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.

No activity recorded in this window. Try a wider timeframe.

Clinical trials

5 sponsors · 0 new · 0 completed in the last 12 months (net +0)

The current development programme across all trial phases.

Clinical programme
6
All trials
0
Active
2
Late-stage
6
Completed
Recently completed

A Phase 2, Randomized, Double-blind, Parallel Group, Placebo Controlled Study to Evaluate the Effect of Tezepelumab on Airway Inflammation in Adults With Inadequately Controlled Asthma on Inhaled Corticosteroids and at Least One Additional Asthma Controller (CASCADE)

Phase 2 · Completed · AstraZeneca

A PHASE 3 RANDOMIZED WITHDRAWAL, DOUBLE-BLIND, PLACEBO-CONTROLLED, MULTI-CENTER STUDY INVESTIGATING THE EFFICACY AND SAFETY OF PF-04965842 IN SUBJECTS AGED 12 YEARS AND OVER, WITH MODERATE TO SEVERE ATOPIC DERMATITIS WITH THE OPTION OF RESCUE TREATMENT IN FLARING SUBJECTS

Phase 3 · Completed · Pfizer

A Randomized, Double-blind, Placebo-controlled Study to Investigate the Efficacy and Safety of Dupilumab Monotherapy in Patients ≥12 to <18 Years of Age, With Moderate-to-severe Atopic Dermatitis

Phase 3 · Completed · Regeneron Pharmaceuticals

A Pilot Study to Compare Responses to Cat Allergen Exposure Using the Environmental Exposure Chamber (EEC) and Nasal Allergen Challenge (NAC)

Early Phase 1 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Epicutaneous Immunotherapy (EPIT) for Peanut Allergy: A Randomized, Double-Blind, Placebo-Controlled, Phase II Study in Children and Adults (DAIT COFAR6)

Phase 2 · Completed · National Institute of Allergy and Infectious Diseases (NIAID)

Cellular Inflammation Characterization of Nasal Challenges With Fine and Ultrafine Particles

Phase 1 · Completed · University of California, Los Angeles

Research activity

2 papers

Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.

Major themes6
  • Betacoronavirus1
  • Coronavirus Infections1
  • Drug Hypersensitivity1
  • Hypersensitivity, Immediate1
  • Pandemics1
  • Pneumonia, Viral1
Leading journals2
  • Allergy1
  • The Journal of allergy and clinical immunology1
Leading researchers8
  • Altman MC1
  • Atanaskovic-Markovic M1
  • Bacharier LB1
  • Barbaud A1
  • Becker P1
  • Bircher AJ1
  • Brockow K1
  • Busse WW1
Affiliations (unnormalised)6
  • Allergy Clinic1
  • Ankara University School of Medicine1
  • Boston University School of Medicine1
  • Centro Hospitalar Universitário de S João1
  • Clinical Immunology and Allergy Unit1
  • Columbia University College of Physicians and Surgeons1

Reference

Authoritative identity, definition & identifiers.

Defined in MeSH

Hypersensitivity reactions which occur within minutes of exposure to challenging antigen due to the release of histamine which follows the antigen-antibody reaction and causes smooth muscle contraction and increased vascular permeability.

Identifiers
MeSHHypersensitivity, Immediate
References & data sources
  • Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
  • Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
  • Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
  • Related entities are derived from literature co-mention (studied together) — associative, not causal.